What is the recommended dosage of Zetia (ezetimibe) for adults and children?

Zetia (Ezetimibe) Dosing

The recommended dose of Zetia is 10 mg once daily for all adults and children ≥10 years of age, taken with or without food, and may be administered at the same time as a statin or fenofibrate. 1

Adult Dosing

• Standard dose: 10 mg orally once daily 1
• Timing flexibility: Can be taken in the morning or evening without regard to meals 1
• No dose adjustment needed for elderly patients, renal impairment of any severity, or mild hepatic impairment 1
• Avoid in moderate-to-severe hepatic impairment 1

Combination Therapy Considerations

• With statins: Administer ezetimibe at the same time as the statin for convenience; this is the preferred approach for high-risk patients requiring additional LDL-C lowering beyond maximally tolerated statin therapy 2, 3
• With bile acid sequestrants: Dose ezetimibe ≥2 hours before or ≥4 hours after the sequestrant to avoid reduced absorption 1
• With fenofibrate: May be co-administered for mixed hyperlipidemia 1

Higher Doses (Off-Label)

• One retrospective study showed that ezetimibe 20 mg daily (off-label) produced an additional 10.3% LDL-C reduction beyond the 10 mg dose in patients on concomitant statin therapy, with no increase in side effects 4
• This higher dose is not FDA-approved and should only be considered in patients failing to reach targets on standard therapy 4

Pediatric Dosing

• Age ≥10 years: 10 mg once daily 1
• Age 6–9 years: 10 mg once daily is supported by clinical trial data in children with familial or nonfamilial hypercholesterolemia 5
• Age <6 years: Not studied; pharmacokinetic data unavailable 1
• Pre-menarchal girls: Not studied 1

Pediatric Combination Therapy

• Ezetimibe co-administered with simvastatin (10–40 mg) in adolescents aged 10–17 years with heterozygous familial hypercholesterolemia produced an additional 15% LDL-C reduction compared to simvastatin alone 1
• Ideal age to start statin + ezetimibe combination: 8–12 years for children with familial hypercholesterolemia who do not meet LDL-C targets on lifestyle modification alone 6
• Doses of simvastatin >40 mg combined with ezetimibe have not been studied in adolescents 1

Clinical Context for Dosing Decisions

When to Add Ezetimibe

• Very high-risk patients (secondary prevention): Add ezetimibe 10 mg when LDL-C remains ≥70 mg/dL (1.8 mmol/L) despite maximally tolerated statin 2, 3
• Post-myocardial infarction: Initiate ezetimibe + high-intensity statin early (≤12 weeks after discharge) rather than delaying; early combination therapy reduces 3-year MACE by 1.9% absolute risk compared to no ezetimibe 7
• Statin-intolerant patients: Ezetimibe 10 mg as monotherapy reduces LDL-C by approximately 18–20% and is the first-line non-statin option 2, 3

Common Pitfalls

• Do not delay ezetimibe in high-risk patients waiting to "see if statin alone works"—early combination therapy after MI prevents avoidable cardiovascular events 7
• Do not skip ezetimibe and jump directly to PCSK9 inhibitors; ezetimibe must be trialed first as it is cost-effective and guideline-mandated 2
• Do not use ezetimibe in moderate-to-severe hepatic impairment 1
• Do not co-administer with bile acid sequestrants without proper spacing (≥2 hours before or ≥4 hours after) 1

Safety Monitoring

• No routine laboratory monitoring is required for ezetimibe monotherapy 1
• When combined with statins, monitor liver enzymes and creatine kinase as per statin guidelines; ezetimibe adds minimal additional risk (1.1% vs 0.6% muscle symptoms requiring discontinuation) 3
• In pediatric patients on combination therapy, monitor ALT/AST and CPK; transaminase elevations ≥3× ULN occurred in 3% of adolescents on ezetimibe + simvastatin 1